BSGM - バイオシグ・テクノロジ―ズ （BioSig Technologies Inc.）

WESTPORT, CT / ACCESSWIRE / May 25, 2023 / Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies'' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual…

WESTPORT, CT / ACCESSWIRE / May 25, 2023 / Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies'' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in New Orleans, LA, last week. The platform''s precision signal-capturing technology is meant to improve the speed, accuracy and precision of cardiac ablation, a widely-used surgery to treat atrial fibrillation. All three studies showed significant improvements over the conventional methods used for the procedure, putting BioSig on track for a successful commercial launch of the platform in a global cardiac ablation market projected to exceed $14 billion by 2032. 75,000 Ablation Procedures Are Performed Every Year In The U.S. According to the Centers for Disease Control (CDC), approximately 12.1 million Americans will have atrial fibrillation (AF) by 2030. AF is responsible for over 750,000 hospitalizations in the United States every year, according to the National Institutes of Health.

Leading physicians from Cleveland Clinic to present data from three posters that showcase the Company’s novel PURE EP Platform Westport, CT, May 03, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that

Advent Technologies Holdings (ADN) +34% enter into joint development pact.ZyVersa Therapeutics (ZVSA) +26%. BioSig Technologies (BSGM) +17%

In last trading session, BioSig Technologies Inc. (NASDAQ:BSGM) saw 0.38 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $1.05 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $51.04M. That closing price of BSGM’s stock is … BioSig Technologies Inc. (NASDAQ:BSGM) -8.70% Down Over Last Week, What Happens Next? Read More »

Westport, CT, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM ) ("BioSig" or the "Company"), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would participate in the Kansas City Heart Rhythm Symposium, due to take place on August 21-22, 2021 at the Overland Park Convention Center. The Company''s clinical and commercial teams will host product demonstrations that will showcase the latest clinical data and the newest software features of its PURE EP(tm) System, the non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. The Company''s technology will also be featured in a presentation at the Technology Theater during the Symposium. The presentation titled "PURE EP(tm) - A New Standard in Signal Processing" will be conducted during the sessions beginning at noon on Saturday, August 21, 2021, at the Technology Theatre.

Westport, CT, July 12, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EP(tm) 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. Davids Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA.

Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering were $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig.

According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM ) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP System in April 2021. Under the terms of the commercial transaction, the Foundation is acquiring the PURE EP System for clinical use at Mayo Clinic Phoenix Campus in Arizona. Previously, the institution acquired multiple PURE EP Systems for its Florida and Minnesota Mayo Clinic campuses. To date, more than 1,000 patient cases have been conducted using the PURE EP System by 52 physicians across nine clinical sites. The company is excited about the new sale to the Mayo Clinic and is confident that this denotes the efficacy and potential of its technologies. In fact, its not just the Mayo Clinic Full story available on Benzinga.com

Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering were $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig.

According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM ) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP System in April 2021. Under the terms of the commercial transaction, the Foundation is acquiring the PURE EP System for clinical use at Mayo Clinic Phoenix Campus in Arizona. Previously, the institution acquired multiple PURE EP Systems for its Florida and Minnesota Mayo Clinic campuses. To date, more than 1,000 patient cases have been conducted using the PURE EP System by 52 physicians across nine clinical sites. The company is excited about the new sale to the Mayo Clinic and is confident that this denotes the efficacy and potential of its technologies. In fact, its not just the Mayo Clinic Full story available on Benzinga.com

Med-tech firms raising money in public or private financings, including: Biosig Technologies, Nyxoah.

BioSig Technologies Inc (NASDAQ: BSGM ) has priced its previously announced underwritten public offering of 2.5 million shares at $4.00 per share , representing a discount of 8% from the last close price of $4.35 on Thursday. The gross proceeds will be approximately Full story available on Benzinga.com

Westport, CT, July 02, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering are expected to be approximately $10 million, or approximately $11.5 million if the underwriter exercises its 30-day option to purchase an additional 15% of the number of shares of common stock offered in the public offering in full, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig. The offering is expected to close on July 7, 2021, subject to the satisfaction of customary closing conditions.